Table 1.
Variables | Univariate analysis |
Multivariate analysis |
||||
---|---|---|---|---|---|---|
HR | 95% CI | P-value | HR | 95% CI | P-value | |
Age | 1.028 | 1.007–1.049 | 0.010* | 1.031 | 1.009–1.053 | 0.006* |
Gender, male | 0.813 | 0.541–1.222 | 0.319 | – | – | – |
Race | ||||||
Black | 1.210 | 0.324–4.519 | 0.777 | – | – | – |
White | 1.264 | 0.511–3.127 | 0.613 | – | – | – |
Stage | ||||||
2 | 2.350 | 1.078–5.125 | 0.032* | – | – | – |
3 | 1.055 | 0.129–8.643 | 0.960 | – | – | – |
4 | 1.594 | 0.327–7.780 | 0.564 | – | – | – |
Tumor purity | 0.454 | 0.214–0.963 | 0.040* | 0.687 | 0.288–1.637 | 0.396 |
B cells | 1.664 | 0.112–24.800 | 0.712 | – | – | – |
CD8+ T cells | 18.719 | 1.056–331.683 | 0.046* | 6.825 | 0.184–253.697 | 0.298 |
CD4+ T cells | 0.010 | 0.000–1.822 | 0.083 | – | – | – |
Macrophages | 0.861 | 0.026–28.261 | 0.933 | – | – | – |
Neutrophils | 476.588 | 0.286–795522.500 | 0.103 | – | – | – |
Dendritic cells | 2.292 | 0.444–11.841 | 0.322 | – | – | – |
ANLN | 1.573 | 1.297–1.908 | < 0.001* | 1.323 | 0.879–1.991 | 0.179 |
ASPM | 1.749 | 1.322–2.312 | < 0.001* | 0.670 | 0.366–1.228 | 0.195 |
CDK1 | 1.746 | 1.354–2.252 | < 0.001* | 1.041 | 0.514–2.108 | 0.912 |
CEP55 | 1.765 | 1.387–2.246 | < 0.001* | 1.626 | 0.812–3.253 | 0.170 |
DLGAP5 | 1.745 | 1.367–2.227 | < 0.001* | 0.594 | 0.359–0.983 | 0.043* |
NUSAP1 | 1.769 | 1.358–2.305 | < 0.001* | 1.061 | 0.550–2.044 | 0.861 |
References included: female for gender, white for race, and stage 1 for tumor stage. *P < 0.05 was considered statistically significant. TIMER, Tumor Immune Estimation Resource; HR, hazard ratio; CI, confidence interval.